Cover |
May 01, 2025 |
|---|---|
| Entity Addresses [Line Items] | |
| Document Type | POS AM |
| Amendment Flag | true |
| Amendment Description | This Post-Effective Amendment No. 1 (this “Post-Effective Amendment No. 1”) to the Registration Statement on Form F-1 (File No. 333-281489) (the “Registration Statement”) is being filed pursuant to our undertaking in the Registration Statement to update and supplement information contained in the Registration Statement, as originally filed on August 12, 2024, and declared effective by the Securities and Exchange Commission (the “SEC”) on August 19, 2024, as to incorporate by reference the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025. The Registration Statement originally covered a resale (the “Offering”) by the selling shareholders identified in this prospectus, of up to an aggregate of 4,349,010,000 ordinary shares, nominal value £0.001 per share (the “Ordinary Shares”), of Biodexa Pharmaceuticals PLC, represented by 434,901 American Depositary Shares (the “Depositary Shares”) consisting of (i) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares issuable upon the exercise of Series J warrants, or Series J Warrants, issued in a July 2024 private placement, or the July 2024 Private Placement, (ii) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares, issuable upon the exercise of Series K warrants, or Series K Warrants, issued in the July 2024 Private Placement, and (iii) 85,250,000 Ordinary Shares represented by 8,525 Depositary Shares, issuable upon the exercise of placement agent warrants, or the July 2024 Placement Agent Warrants, issued in the July 2024 Private Placement. The information included in this filing updates the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No. 1. Accordingly, this Post-Effective Amendment No. 1 concerns only the offer and sale of Ordinary Shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised. All applicable registration fees were paid at the time of the original filing of the Registration Statement. |
| Entity Registrant Name | Biodexa Pharmaceuticals PLC |
| Entity Central Index Key | 0001643918 |
| Entity Incorporation, State or Country Code | X0 |
| Entity Address, Address Line One | 1 Caspian Point |
| Entity Address, Address Line Two | Caspian Way |
| Entity Address, City or Town | Cardiff |
| Entity Address, Postal Zip Code | CF10 4DQ |
| Country Region | +44 |
| City Area Code | 29 |
| Local Phone Number | 20480 180 |
| Entity Filer Category | Non-accelerated Filer |
| Entity Emerging Growth Company | false |
| Document Creation Date | May 01, 2025 |
| Business Contact [Member] | |
| Entity Addresses [Line Items] | |
| Entity Address, Address Line One | 850 Library Ave. |
| Entity Address, Address Line Two | Suite 204 |
| Entity Address, City or Town | Newark |
| Entity Address, State or Province | DE |
| Entity Address, Postal Zip Code | 19711 |
| City Area Code | 302 |
| Local Phone Number | 738-6680 |
| Contact Personnel Name | Donald J. Puglisi |